secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001737287-23-000074
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene reports Q2 2023 net loss of $78.0M; cash extends into 2H 2025
----------------------------------------------------------------------

- Cash, equivalents, and investments $544.5M as of June 30, 2023; raised $87.9M via ATM in Q2.
- Net loss $78.0M ($0.53/share) including $16.6M non-cash stock-based comp.
- ALLO-501A Phase 2 ALPHA2 enrollment expected to complete 1H 2024; data readout by year-end 2024.
- Long-term data from ALPHA/ALPHA2 trials showed complete response rates similar to approved autologous CAR T.
- Cash runway now projected into 2H 2025; 2023 operating expense guidance ~$340M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000074/0001737287-23-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000074/allo-20230802.htm
  HTML page:      https://secwatch.observer/filing/0001737287-23-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer